Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11 April 2014
2019_biotech_test_vial_discovery_big

The effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed US and European hematological oncologists' prescribing decisions for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

In addition, according to a new report from Decision Resources, US and European hematological oncologists, as well as US payers indicate that improving overall survival is one of the greatest unmet needs in R/R CLL/SLL.

The novel mechanism of action of first-in-class kinase inhibitors ibrutinib (Johnson & Johnson (NYSE: JNJ)/Janssen/Pharmacyclics' Imbruvica [ibrutinib] and idelalisib (Gilead Sciences; Nasdaq: GILD) has elicited great enthusiasm from interviewed experts. These experts perceive that ibrutinib and idelalisib offer a major advantage in efficacy compared with the current major-market sales and patient share leader, FCR*.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology